Custom Antibodies


"It has been my experience that NeoClone's approach to antibody screening helped a client efficiently and effectively select good antibody candidates early in their development process, allowing them to focus their efforts on clones that had a real chance at meeting their needs."

Gary A. Ascani President, Medical Ventures Consulting, LLC

Robust Hybridomas for Reliable Custom mAbs

NeoClone has been developing high quality custom monoclonal antibodies for pharmaceutical, biotech, academic and federal laboratory customers for over 12 years.  Using murine hybridoma technology, we have been quite successful at generating diverse panels of very high affinity monoclonal antibodies against difficult targets, such as:

  • small peptides
  • point mutations
  • post-translationally modified proteins.

Discovering great antibodies starts with generating a robust immune response against the antigen of interest. We understand and appreciate that every antigen is unique.  Each project is discussed thoroughly before starting to be sure we'll meet your needs. We also provide advice and technical expertise throughout the project to help you make the right decision at each step.

Antibody Characterization

Most antibody developers only test if an antibody will recognize an antigen in an ELISA or a Western Blot assay. More often than not, however, these baseline assays may not provide you with the full range of information you need for a successful project. We believe that antibody developers should supply more, not less, information to clients.

That's why nearly all NeoClone projects involve multiple screenings, most of which are done in the early, discovery stage. Our extensive experience tells us that robust screening, at this point in the NeoAb process, will result in better focus on which clones to move into the development phase.  Proper antibody characterization also helps determine the chances of overall project success.

What assays should be done in an antibody development project?  Like much of the rest of the antibody development process, it depends on the target and desired end-use of the antibody. Of course you screen against the antigen, but you may also need to know:

  • Does your antibody cross-react in other species?
  • Does the antibody have certain affinity requirements?
  • Are there specific applications in which you need the antibody to work - like IHC or IP?
  • Does the antibody work against endogenous protein?

These are but a few examples. Once we understand your specific needs, we can create a targeted approach to find the appropriate clones for development. At this point, we can work with you in one of two ways; we can either go into development with our selection of the best supernates, or we can send you the developed supernates so that you may complete your own screening while we complete ours. Many of our customers find the latter, collaborative approach to be the most effective.

In short, we believe that best way to develop great antibodies on a repeatable basis is by ensuring each antibody is fully characterized with robust screening.

If you are interested in having the very best monoclonal antibodies for your research or diagnostic assay, contact us today at